NeuroOne Medical Technologies (NASDAQ:NMTC) and Oncology Institute (NASDAQ:TOI) Financial Review

NeuroOne Medical Technologies (NASDAQ:NMTC) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares NeuroOne Medical Technologies and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-78.34%	-119.92%	-78.86%
Oncology Institute	-11.45%	N/A	-33.70%

Volatility and Risk

NeuroOne Medical Technologies has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500.

Insider & Institutional Ownership

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 8.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares NeuroOne Medical Technologies and Oncology Institute”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10 million	3.27	-$3.61 million	($1.02)	-4.61
Oncology Institute	$502.73 million	0.76	-$60.61 million	($0.56)	-6.89

NeuroOne Medical Technologies has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for NeuroOne Medical Technologies and Oncology Institute, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1	1	3	0	2.40
Oncology Institute	1	0	4	0	2.60

NeuroOne Medical Technologies presently has a consensus target price of $11.90, indicating a potential upside of 153.19%. Oncology Institute has a consensus target price of $7.00, indicating a potential upside of 81.35%. Given NeuroOne Medical Technologies’ higher possible upside, equities research analysts clearly believe NeuroOne Medical Technologies is more favorable than Oncology Institute.

Summary

Oncology Institute beats NeuroOne Medical Technologies on 8 of the 14 factors compared between the two stocks.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.